1. Pink Sheet
  2. >>Market Access
  3. >>PBMs

PBM Reform Legislation: PhRMA ‘Laser Focused’ On Passage This Year

 
• By Cathy Kelly

But the prospects for attaching the legislation to a federal spending package in December will be dependent on the outcome of the upcoming elections.

Brukinsa final win
Is the finish line near for legislation targeting PBM and rebate reform? • Source: Shutterstock

The extent of bipartisan congressional support for pharmacy benefit manager reform legislation is encouraging drug industry and other stakeholders to hope a bill can pass before the end of the year.

Key Takeaways
  • PhRMA will continue pushing for congressional passage of meaningful PBM reform legislation before the end of the year, CEO Steve Ubl said.
  • The strong bipartisan support for reform in Congress will help, but a lot will depend on whether PBM legislation can ride with an end-of-year federal spending package

“As we look at the lame duck session, this is one of those rare areas of bipartisan agreement in health policy and we’re going to be laser focused on getting it over the finish line,” Pharmaceutical Research and Manufacturers

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from PBMs

More from Government Payers

House Budget Bill Includes Delayed Orphan Fix, Also Risks Downstream Cell and Gene Coverage

 
• By Sarah Karlin-Smith

The first two classes of negotiated drugs under the Inflation Reduction Act would not benefit from a rare disease adjustment House Republicans included in their reconciliation package.

Trump’s Rx Pricing Order: The Best-Case And Worst-Case Scenarios

 
• By Derrick Gingery

US trade and tariff leverage might successfully push European and other countries to pay more for medicines, but if not, President Trump’s executive order includes potential US drug withdrawal and other options to entice industry to lower US prices.

Medicare Negotiation Does Not Violate Due Process, Appeals Court Rules, Other Suits At Risk

 
• By Cathy Kelly

Decision in AstraZeneca’s lawsuit against the Health and Human Services Department is a precedent-setting victory for the government and a blow to manufacturer efforts to block the price negotiation program.